TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna and Merck report that adding personalized mRNA vaccine intismeran to Keytruda reduced the risk of melanoma recurrence or death by 42% over two years compared with Keytruda and placebo. The companies’ reported results also showed higher rates of survival without recurrence and distant metastasis, but detailed trial data and longer-term outcomes remain pending.
Moderna and Merck said their personalized mRNA cancer vaccine, intismeran, reduced the risk of melanoma recurrence or death by 42% over two years when given with Keytruda, compared with Keytruda and placebo in a Phase 3 trial. The findings concern patients with resected melanoma—cancer that had been surgically removed—and the companies’ announcement reports improved recurrence-free outcomes, though the full study results are not provided in the source material.
The trial compared intismeran plus Keytruda with Keytruda plus placebo. According to the report of the companies’ announcement, after two years, 82% of patients receiving the vaccine combination were alive without cancer recurrence, compared with 70% in the comparison group. The 42% figure describes a reduction in the relative risk of recurrence or death; it does not mean that 42% more patients were cured.
For distant metastasis-free survival—remaining alive without cancer returning in a different part of the body—the combination was associated with a 38% reduction in the risk of distant metastasis or death compared with Keytruda and placebo. At the reported assessment, 88.5% of the vaccine group were alive without distant metastasis, compared with 80% of the comparison group.
Intismeran, also called mRNA-4157, is tailored to a patient’s tumor. The report says it contains synthetic mRNA encoding up to 34 mutations identified by comparing the genetic sequences of cancer cells and healthy cells. The aim is to direct an immune response toward features specific to the patient’s cancer. The results are company-reported; the source does not include a full publication or detailed trial analysis.
Potential Gains After Melanoma Surgery
The results point to a possible way to reduce the chance that high-risk melanoma returns after surgery, by adding a personalized vaccine to an existing immunotherapy. Recurrence and distant spread are major concerns even when a tumor has been removed, so improvements in time without either outcome could matter to patients and clinicians weighing post-surgery treatment.
The figures should be read with their specific endpoints in mind. The reported 42% reduction is a relative risk measure, while the two-year rates—82% versus 70%—show the proportion alive without recurrence at that point. The findings do not establish that every patient benefits, nor do they show from the supplied information whether the treatment improves overall survival over a longer period. Any change to care would depend on the complete evidence and regulatory review.
Products Worth Considering
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Navy
Hyperice Normatec Elite Wireless Compression Boots Recovery – Standard Size
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
As an affiliate, we earn on qualifying purchases.
How the Vaccine Targets Each Tumor
The study tested the vaccine in the adjuvant setting: treatment given after surgery, when visible melanoma has been removed but the risk of return remains. Keytruda, Merck’s pembrolizumab, is an immunotherapy used in cancer care. In this trial it was given in both groups, allowing researchers to compare the added vaccine with placebo against a shared Keytruda treatment.
The companies’ reported Phase 3 results follow a five-year Phase 2 trial cited in the source report. That earlier study showed a 49% reduction in risk of recurrence or death and a 59% reduction in risk of distant metastasis or death. The Phase 3 estimates reported now are smaller, but come from a later-stage trial; the supplied material does not provide enough detail to compare the studies’ populations, methods, or statistical results directly.
“The trial is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma.”
— Dean Li, president of Merck Research Laboratories, as quoted in the company announcement
Full Trial Evidence Still Pending
The source reports figures from a company announcement, not a complete scientific paper. It does not provide the number of participants, confidence intervals, statistical significance details, side-effect rates, or a full account of trial design. Those details are needed to judge the precision of the estimates and weigh potential benefits against risks.
It is also unclear from the supplied information how the results vary across patient subgroups, how long any benefit persists beyond the reported two-year assessment, or whether the combination affects overall survival. The 42% and 38% figures refer to different outcomes and should not be treated as measures of the same effect. The source does not state whether regulators have reviewed or approved intismeran for this use.
Publication and Regulatory Review
The next key step is access to the full Phase 3 data, including trial methods, statistical analyses, safety findings, and follow-up beyond two years. Those results would allow clinicians and independent reviewers to assess how the reported risk reductions translate into treatment decisions for people with resected melanoma.
Any potential availability of intismeran for this use will depend on further evidence and the applicable regulatory process. The announcement alone does not establish approval or a change in treatment guidelines. Patients should discuss postoperative melanoma care with their oncology team rather than infer an individual treatment recommendation from the reported headline figures.
Key Questions
What did the Phase 3 trial report?
According to Moderna and Merck’s reported results, intismeran plus Keytruda reduced the risk of melanoma recurrence or death by 42% over two years compared with Keytruda and placebo. The announcement also reported improved distant metastasis-free survival.
Does a 42% risk reduction mean 42% more patients were cured?
No. The 42% figure is a relative reduction in risk of recurrence or death, not a cure rate or a 42-percentage-point increase. The reported two-year proportion alive without recurrence was 82% with the combination and 70% with Keytruda and placebo.
What is intismeran?
Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed using mutations identified in an individual patient’s tumor. The trial tested it alongside Keytruda after melanoma surgery.
Is the vaccine approved for melanoma treatment?
The source material does not say that intismeran is approved for this use. The reported trial results are not, by themselves, confirmation of regulatory approval or a change in standard treatment.
Source: hn
